This brand name is authorized in Tunisia.
The drug PRIFAL contains one active pharmaceutical ingredient (API):
1
|
UNII
3B7O9ZC520 - PRIFINIUM BROMIDE
|
|
Prifinium is an anticholinergic preferably acting at muscarinic receptors in the gastrointestinal tract. Prifinium’s mechanism of action is believed to be due to its activity as an antispasmodic agent. It is used primarily in the treatment of irritable bowel syndrome. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| A03AB18 | Prifinium bromide | A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AB Synthetic anticholinergics, quaternary ammonium compounds |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| TN | Direction de la Pharmacie et du Médicament | 9254151 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.